HIV New Product Introduction Toolkit

The CHAI Simple Tool is a morbidity-based forecasting tool that quantifies ARV needs over a three year period for an HIV/AIDS treatment...

In December 2022, 40+ community groups and an additional 45+ individuals released a community position statement calling on the global...

Updated: Feb 15, 2023 The CHAI Simple Tool is a morbidity-based forecasting tool that quantifies ARV needs over a three year period for...

CHAI developed these frequently asked questions (FAQs) to lay out information for communities and PLHIV on the subject of DRV/r (400/50...

CHAI has developed a generic training curriculum that is intended to be adapted for local contexts and their respective training plans.

Darunavir (DRV) is a best-in-class protease inhibitor (PI) used in combination with other antiretroviral (ARV) drugs for the...

CHAI is pleased to share a customizable guide to assist healthcare workers with prescribing and dispensing second-line (2L) DRV/r...

A presentation with the latest information on DRV/r (400/50mg) and considerations for adult second line treatment optimization.

CHAI developed these frequently asked questions (FAQs) to lay out information for national HIV programs considering the adoption and...

Keeping an adequate stock of ARVs on hand is important for multiple reasons. Too much stock, and programs run the risk of products...

As national programs continue to rollout new generic ARVs, there is a need for routine, careful monitoring of product uptake to ensure...